HC Wainwright Has Positive Forecast for ELTX FY2026 Earnings

Elicio Therapeutics, Inc. (NASDAQ:ELTX) – Equities researchers at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Elicio Therapeutics in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($1.60) per share for the year, up from their prior forecast of ($1.83). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Elicio Therapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for Elicio Therapeutics’ Q4 2026 earnings at ($0.31) EPS, Q1 2027 earnings at ($0.29) EPS, Q2 2027 earnings at ($0.28) EPS, Q3 2027 earnings at ($0.29) EPS, Q4 2027 earnings at ($0.27) EPS and FY2027 earnings at ($1.12) EPS.

A number of other research analysts have also recently weighed in on the company. Wall Street Zen upgraded Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings upgraded shares of Elicio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Finally, B. Riley Financial lowered their price objective on shares of Elicio Therapeutics to $8.00 and set a “buy” rating on the stock in a research note on Thursday, September 24th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Elicio Therapeutics Stock Up 1.2%

ELTX opened at $1.63 on Thursday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.43 and a current ratio of 3.43. The company has a market cap of $46.14 million, a price-to-earnings ratio of -0.87 and a beta of 1.64. Elicio Therapeutics has a one year low of $1.25 and a one year high of $16.00. The business’s fifty day moving average is $1.85 and its two-hundred day moving average is $6.49.

Elicio Therapeutics (NASDAQ:ELTX) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.14.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Ieq Capital LLC acquired a new stake in Elicio Therapeutics during the 3rd quarter valued at $47,000. Shah Capital Management acquired a new position in shares of Elicio Therapeutics in the third quarter worth $2,275,000. BlackRock Inc. acquired a new position in shares of Elicio Therapeutics in the second quarter worth $2,995,000. Deutsche Bank AG acquired a new position in shares of Elicio Therapeutics in the second quarter worth $49,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Elicio Therapeutics in the second quarter valued at $62,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Elicio Therapeutics Company Profile

Elicio Therapeutics, Inc. (NASDAQ: ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the immune system against cancer. The company’s approach is based on its proprietary Amphiphile technology, which is intended to direct vaccine components and immune-stimulating agents to lymph nodes, where important immune responses are initiated. Elicio’s lead program is ELI-002, a therapeutic cancer vaccine being developed for patients with tumors containing mutations in the KRAS gene.